Once daily pre-breakfast lixisenatide provided a significantly greater reduction in PPG (AUC) during a morning test meal versus pre-breakfast liraglutide. Lixisenatide provided significant decreases in postprandial insulin, C-peptide (vs an increase with liraglutide), and glucagon, and better gastrointestinal tolerability than liraglutide (Diabetes, Obesity and Metabolism)